Reuters logo
8 months ago
BRIEF-GTx says primary efficacy endpoint met in Enobosarm 9 mg cohort
December 8, 2016 / 12:29 PM / 8 months ago

BRIEF-GTx says primary efficacy endpoint met in Enobosarm 9 mg cohort

Dec 8 (Reuters) - GTx Inc

* Primary efficacy endpoint met in Enobosarm 9 mg cohort

* Enobosarm 9 mg appears to be safe and generally well tolerated

* Plans to report top-line clinical results following completion of clinical trial, which is anticipated to occur in mid-2017

* Trial will continue as planned with a daily dose of either Enobosarm 9 mg or 18 mg

* GTx reports results from ongoing Enobosarm phase 2 clinical trial in er+/ar+ breast cancer Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below